<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "Triple negative breast cancer" AND "therapy"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Targeting the Id1-Kif11-Aurka axis in triple negative breast cancer using combination therapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/760686v1">Link</a></p><p><b>Date:</b> 2019-09-11</p><p><b>Authors:</b> Reshma Murali ... Radhika Nair</p><p><b>Downloads:</b> 180</p><p><b>Relevance Score:</b> 1.0</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Evidence points to breast cancer following a hierarchical model, with Cancer Stem Cells (CSCs) driving critical phenotypes of the bulk tumor.  Chemoresistant CSCs are not an abstract concept but have clinical consequences as they drive relapse and ultimately lead to mortality in patients, making it imperative to understand how these subpopulations of cells survive.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31893312">Link</a></p><p><b>Date:</b> 2020-01-01</p><p><b>Authors:</b> Parviz Mammadzada ...  Helder André</p><p><b>Journal:</b> Cell. Mol. Life Sci.</p><p><b>IF (7 or above):</b> 7.03</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Understanding the mechanisms that underlie age-related macular degeneration (AMD) has led to the identification of key molecules.  Hypoxia-inducible transcription factors (HIFs) have been associated with choroidal neovascularization and the progression of AMD into the neovascular clinical phenotype  ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/215954v1">Link</a></p><p><b>Date:</b> 2017-11-08</p><p><b>Authors:</b> Aurélie S Cazet ... Alexander Swarbrick</p><p><b>Downloads:</b> 776</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The cellular and molecular basis of stromal cell recruitment, activation and crosstalk in carcinomas is poorly understood, limiting the development of targeted anti-stromal therapies.  In mouse models of triple negative breast cancer (TNBC), Hh ligand produced by neoplastic cells reprogrammed cancer-associated fibroblast (CAF) gene expression, driving tumor growth and metastasis.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Role of non-coding RNAs and RNA modifiers in cancer therapy resistance.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32122355">Link</a></p><p><b>Date:</b> 2020-03-03</p><p><b>Authors:</b> Xinyi Zhang ...  Yongguang Tao</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> As the standard treatments for cancer, chemotherapy and radiotherapy have been widely applied to clinical practice worldwide.  However, the resistance to cancer therapies is a major challenge in clinics and scientific research, resulting in tumor recurrence and metastasis.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: ANTENNA, a Multi-Rank, Multi-Layered Recommender System for Inferring Reliable Drug-Gene-Disease Associations: Repurposing Diazoxide as a Targeted Anti-Cancer Therapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/192385v2">Link</a></p><p><b>Date:</b> 2017-09-22</p><p><b>Authors:</b> Annie Wang ... Lei Xie</p><p><b>Downloads:</b> 401</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Existing drug discovery process follows a reductionist model of 'one-drug-one-gene-one-disease,' which is not adequate to tackle complex diseases that involve multiple malfunctioned genes.  The availability of big omics data offers new opportunities to transform the drug discovery process into a new paradigm of systems pharmacology that focuses on designing drugs to target molecular interaction networks instead of a single gene.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32114499">Link</a></p><p><b>Date:</b> 2020-03-02</p><p><b>Authors:</b> Catarina Pinto ...  Sebastian Kobold</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunotherapy has moved to the forefront of cancer treatment, illustrated by the accelerating pace of novel therapy approvals.  In this complex environment, scientists rely on cutting edge conferences to stay informed.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: STAT3 and GR cooperate to drive basal-like triple negative breast cancer gene expression and proliferation.</h4><p><a href="https://www.biorxiv.org/content/10.1101/730606v1">Link</a></p><p><b>Date:</b> 2019-08-09</p><p><b>Authors:</b> Megan E Conway ... Katherine E Varley</p><p><b>Downloads:</b> 274</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Breast cancers can be divided into subtypes with different prognoses and treatment responses based on global gene expression differences.  Luminal breast cancer gene expression and proliferation are driven by the transcription factors Estrogen Receptor alpha (ER), FOXA1 and GATA3.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: PARP and PARG inhibitors in cancer treatment.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32029455">Link</a></p><p><b>Date:</b> 2020-02-07</p><p><b>Authors:</b> Dea Slade</p><p><b>Journal:</b> Genes Dev.</p><p><b>IF (7 or above):</b> 8.23</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Oxidative and replication stress underlie genomic instability of cancer cells.  Amplifying genomic instability through radiotherapy and chemotherapy has been a powerful but nonselective means of killing cancer cells.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: The inhibitory effects of butein on cell proliferation and TNF-α-induced CCL2 release in racially different triple negative breast cancer cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/596080v1">Link</a></p><p><b>Date:</b> 2019-04-01</p><p><b>Authors:</b> Patricia Mendonca ... Karam F.A. Soliman</p><p><b>Downloads:</b> 154</p><p><b>Relevance Score:</b> 0.71</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Breast cancer drug resistance is the leading cause of cancer-related mortality in women, and triple negative breast cancer (TNBC) is the most aggressive subtype, affecting African American women more aggressively compared to Caucasians.  Of all cancer-related deaths, 15 to 20% are associated with inflammation, where proinflammatory cytokines have been implicated in the tumorigenesis process.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32138762">Link</a></p><p><b>Date:</b> 2020-03-06</p><p><b>Authors:</b> Shaoquan Zheng ...  Xiaoming Xie</p><p><b>Journal:</b> J Hematol Oncol</p><p><b>IF (7 or above):</b> 8.71</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer with highly invasive ability and metastatic nature to the lymph nodes.  Long non-coding RNAs (lncRNAs) have been widely explored in cancer tumorigenesis and progression.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Application of Polymersomes Engineered to Target P32 Protein for Detection of Small Breast Tumors in Mice</h4><p><a href="https://www.biorxiv.org/content/10.1101/187716v3">Link</a></p><p><b>Date:</b> 2017-09-12</p><p><b>Authors:</b> Lorena Simón-Gracia ... Tambet Teesalu</p><p><b>Downloads:</b> 568</p><p><b>Relevance Score:</b> 0.43</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Triple negative breast cancer (TNBC) is the deadliest form of breast cancer and its successful treatment critically depends on early diagnosis and therapy.  The multi-compartment protein p32 is overexpressed and present at cell surfaces in a variety of tumors, including TNBC, specifically in the malignant cells and endothelial cells, and in macrophages localized in hypoxic areas of the tumor.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32171307">Link</a></p><p><b>Date:</b> 2020-03-16</p><p><b>Authors:</b> Zhenzhen Xu ...  Bin Zhu</p><p><b>Journal:</b> J Hematol Oncol</p><p><b>IF (7 or above):</b> 8.71</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Conventional trial design and analysis strategies fail to address the typical challenge of immune-oncology (IO) studies: only a limited percentage of treated patients respond to the experimental treatment.  Treating non-responders, we hypothesize, would in part drive non-proportional haz ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/209288v1">Link</a></p><p><b>Date:</b> 2017-10-26</p><p><b>Authors:</b> Zhixian Liu ... Xiaosheng Wang</p><p><b>Downloads:</b> 762</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: Triple-negative breast cancer (TNBC) is a high-risk malignancy due to its high capacity for invasion and lack of targeted therapy.  Immunotherapy continues to demonstrate efficacy in a variety of cancers, and thus may be a promising strategy for TNBC given the limited therapeutic options currently available for TNBC.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Vasculogenic mimicry in carcinogenesis and clinical applications.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32169087">Link</a></p><p><b>Date:</b> 2020-03-14</p><p><b>Authors:</b> Qingxi Luo ...  Chaojun Duan</p><p><b>Journal:</b> J Hematol Oncol</p><p><b>IF (7 or above):</b> 8.71</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Distinct from classical tumor angiogenesis, vasculogenic mimicry (VM) provides a blood supply for tumor cells independent of endothelial cells.  VM has two distinct types, namely tubular type and patterned matrix type.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: B7-H1(PD-L1) confers chemoresistance through ERK and p38 MAPK pathway in tumor cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/308601v1">Link</a></p><p><b>Date:</b> 2018-04-25</p><p><b>Authors:</b> Xiaosheng Wu ... Haidong Dong</p><p><b>Downloads:</b> 657</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Development of resistance to chemotherapy and immunotherapy is a major obstacle in extending the survival of patients with cancer.  Although several molecular mechanisms have been identified that can contribute to chemoresistance, the role of immune checkpoint molecules in tumor chemoresistance remains underestimated.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32035020">Link</a></p><p><b>Date:</b> 2020-02-08</p><p><b>Authors:</b> Robert H Jones ...  Sacha J Howell</p><p><b>Journal:</b> Lancet Oncol.</p><p><b>IF (7 or above):</b> 34.34</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT.  The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant adva ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: An atlas of infiltrated B-lymphocytes in breast cancer revealed by paired single-cell RNA-sequencing and antigen receptor profiling</h4><p><a href="https://www.biorxiv.org/content/10.1101/695601v1">Link</a></p><p><b>Date:</b> 2019-07-15</p><p><b>Authors:</b> Qingtao Hu ... Yu Zhang</p><p><b>Downloads:</b> 631</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> While it has been well-recognized that T-cell mediated adaptive cellular immunity plays important roles in cancer immune response and tumor control, the roles of B lymphocytes in tumor development and therapy have only been proposed until recently, and are still mostly controversial.  To gain mechanistic insights into the origin and dynamics of tumor infiltrated immune cells, especially B lymphocytes, we combine single-cell RNA-sequencing and antigen receptor lineage analysis to characterize a large number of triple-negative breast cancer (TNBC) infiltrated immune cells and present a comprehensive atlas of infiltrated B-lymphocytes in TNBC, the most aggressive breast cancer subtype.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32181368">Link</a></p><p><b>Date:</b> 2020-03-17</p><p><b>Authors:</b> Yu Chao ...  Zhuang Liu</p><p><b>Journal:</b> Sci Adv</p><p><b>IF (7 or above):</b> 12.53</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Currently, there is a huge demand to develop chemoimmunotherapy with reduced systemic toxicity and potent efficacy to combat late-stage cancers with spreading metastases.  Here, we report several "cocktail" therapeutic formulations by mixing immunogenic cell death (ICD)-inducing chemotherapeutics an ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: TP53 mutations promote immunogenic activity in breast cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/354779v1">Link</a></p><p><b>Date:</b> 2018-06-24</p><p><b>Authors:</b> Zhixian Liu ... Xiaosheng Wang</p><p><b>Downloads:</b> 625</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no any immunotherapeutic strategy for breast cancer (BC).  Thus, it is important to discover biomarkers for identifying the BC patients responsive to immunotherapy.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Macropinocytosis confers resistance to therapies targeting cancer anabolism.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32111826">Link</a></p><p><b>Date:</b> 2020-02-29</p><p><b>Authors:</b> Vaishali Jayashankar ...  Aimee L Edinger</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.8</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Macropinocytic cancer cells scavenge amino acids from extracellular proteins.  Here, we show that consuming necrotic cell debris via macropinocytosis (necrocytosis) offers additional anabolic benefits.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Evolution of an intratumoral ecology susceptible to successive treatment in breast cancer xenografts</h4><p><a href="https://www.biorxiv.org/content/10.1101/249797v2">Link</a></p><p><b>Date:</b> 2018-01-18</p><p><b>Authors:</b> Hyunsoo Kim ... Jeffrey H. Chuang</p><p><b>Downloads:</b> 498</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The processes by which tumors evolve are essential to the efficacy of treatment, but quantitative understanding of intratumoral dynamics has been limited.  Although intratumoral heterogeneity is common, quantification of evolution is difficult from clinical samples because treatment replicates cannot be performed and because matched serial samples are infrequently available.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32127004">Link</a></p><p><b>Date:</b> 2020-03-04</p><p><b>Authors:</b> Juan Xu ...  Jiwei Zhang</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Long noncoding RNAs (lncRNAs) are emerging as critical regulatory elements and play fundamental roles in the biology of various cancers.  However, we are still lack of knowledge about their expression patterns and functions in human colorectal cancer (CRC).</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Reduction of LOXL2-mediated H3K4 oxidation increases chromatin accessibility and promotes chemosensitivity of triple-negative breast cancer cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/416495v1">Link</a></p><p><b>Date:</b> 2018-09-13</p><p><b>Authors:</b> J.P. Cebrià-Costa ... S. Peiró</p><p><b>Downloads:</b> 278</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Oxidation of H3 at lysine 4 (H3K4ox) by lysyl oxidase-like 2 (LOXL2) generates an H3 modification with an unknown physiological function.  We find that LOXL2 and H3K4ox are higher in triple-negative breast cancer (TNBC) cell lines and patient-derived xenographs (PDXs) than those from other breast cancer subtypes.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32122376">Link</a></p><p><b>Date:</b> 2020-03-03</p><p><b>Authors:</b> Heng Zhu ...  Si Shi</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness.  Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising research direction.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Paradigm of Vanadium pentoxide nanoparticle-induced autophagy and apoptosis in triple-negative breast cancer cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/810200v1">Link</a></p><p><b>Date:</b> 2019-10-18</p><p><b>Authors:</b> Parvathy Radhakrishna Pillai Suma ... Ramapurath S Jayasree</p><p><b>Downloads:</b> 217</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chemo-resistance remains the main hurdle to cancer therapy, challenging the improvement of clinical outcomes in cancer patients.  Therefore, exploratory studies to address chemo-resistance through various approaches are highly rewarding.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Verification of EZH2 as a druggable target in metastatic uveal melanoma.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32127003">Link</a></p><p><b>Date:</b> 2020-03-04</p><p><b>Authors:</b> Bei Jin ...  Jingxuan Pan</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Hepatic metastasis develops in ~ 50% of uveal melanoma (UM) patients with no effective treatments.  Although GNAQ/GNA11 mutations are believed to confer pathogenesis of UM, the underlying mechanism of liver metastasis remains poorly understood.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: ADAR1 editing dependency in triple-negative breast cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.31.928911v1">Link</a></p><p><b>Date:</b> 2020-02-02</p><p><b>Authors:</b> Che-Pei Kung ... Jason D. Weber</p><p><b>Downloads:</b> 205</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer.  Unlike other types of breast cancer that can be effectively treated by targeted therapies, no such targeted therapy exists for all TNBC patients.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: miR-425 suppresses EMT and inhibits the development of TNBC (triple-negative breast cancer) by targeting TGF-β 1/SMAD 3 signaling pathway</h4><p><a href="https://www.biorxiv.org/content/10.1101/477877v1">Link</a></p><p><b>Date:</b> 2018-11-26</p><p><b>Authors:</b> Yingping Liu ... Jinglong Chen</p><p><b>Downloads:</b> 164</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Background: EMT has the crucial effect on the progression and metastasis of tumor.  This work will elucidate the role of miR-425 in EMT and development of TNBC.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype</h4><p><a href="https://www.biorxiv.org/content/10.1101/858969v1">Link</a></p><p><b>Date:</b> 2019-11-29</p><p><b>Authors:</b> Alejandro J. Español ... María E. Sales</p><p><b>Downloads:</b> 109</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Triple negative tumors are more aggressive than other breast cancer subtypes and there is a lack of specific therapeutic targets on them.  Since muscarinic receptors have been linked to tumor progression, we investigated the effect of metronomic therapy employing a traditional anti-cancer drug, paclitaxel plus muscarinic agonists at low doses on this type of tumor.</p></div></td></div><td></td></tr></table></div><hr></div></body></html>